Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S341000, C514S380000, C514S398000, C548S243000, C548S316400, C548S317100, C546S274400, C546S272100
Reexamination Certificate
active
06974826
ABSTRACT:
The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kuhl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa et al.
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5650444 (1997-07-01), Caggiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), M.o slashed.ller et al.
patent: 6355664 (2002-03-01), Kelly et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (1998-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/66167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Re., 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc., 121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Barclay et al., “ortho-Diquaternary aromatic compounds. III. Synthesis and reactions of polyalkyltetralones and derivatives,”Canadian Journal of Chemistry, 48(17):2763-2775 (1970).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis, 829-830 (1981).
Blondet et al., “Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-1,2,3,4-Tetrahydro-2-Quinolinone,”Organic Preparation and Procedures Int., 25(2):223-228 (1993).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,” J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci., 87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNF Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Cacchi et al., “Palladium-Catalyzed Triethylammonium Formate Reduction of Aryl Triflates. A Selective Method for the deoxygenation of phenols,”Tetrahedron Letters, 27(45):5541-5544 (1986).
Cantello et al., “A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-diones via Regiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione,”Synlett, 263-264 (1997).
Cantello et al., “The Synthesis of BRL 49653—A Novel and Potent Antihyperglycaemic Agent,”Biorganic&Medicinal Chemistry Letters, 4:1181-1184 (1994).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters, 39:2933-2936 (1998).
Chang et al., “The Upjohn Colony of KkaγMice: A Model for Obese Type II Diabetes,”Elsevier Science Publishers B.V., Biomedical Division, Diabetes, pp. 466-470 (1986).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem. 38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,”Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem., 41:5055-5069 (1998).
Coleman “Diabetes-Obesity Syndromes in Mice,”Diabetes, 31(1):1-6 (Apr. 1982).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl-and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Dawson et al., “Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity,”J. Med. Chemistry, 38:3368-3383 (1995).
Dawson et al., “The Synthetic Chemistry of Retinoids,”Biology, Chemistry, and Medicine, 2ndEdition, Raven Press, Ltd., New York (1994).
Ebisawa et al., “Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity,”Biol. Pharma. Bull., 21(5):547-549 (1998).
Evans et al., “Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetrahedron Letters, 39:2937-2940 (1998).
Farahat et al., “Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis,”Ann. Rheum. Dis., 52: 870-875 (1993).
Faul et al., “Synthesis of Novel Retinoid X Receptor-Selective Retinoids,”J. Org. Chem., 66:5772-5782 (2001).
Ferrell, “Tripping the Switch Fantastic: How A Protein Kinase Cascade Can Convert Graded Inputs into Switch-Like Outputs,”TIBS, 21:460-466 (1996).
Firooznia et al., “Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Coupling Reactions,”Tetrahedron Letters, 40:213-216 (1999).
Förstermann et al., “Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transforming Growth Factor-,”Eur. J. Pharm., 225:161-165 (1992).
Fukuto et al., “Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition,”Annu. Rev. Pharmacol. Toxicol. 35:165-194 (1995).
Gahtan et al., “Inflammatory Pathogenesis in Alzheimer's Disease: Biological Mechanisms and Cognitive Sequeli,”Neurosci: Biobehav, 23:615-633 (1999).
Glauser et al., “Pathogenesis and Potential Strategies for Prevention and Treatment of Septic Shock: An Update,
Al-Shamma Hussien A.
Fanjul Andrea
Pfahl Magnus
Pleynet David P. M.
Spruce Lyle W.
Incyte San Diego Inc.
Lambkin Deborah C.
Needle & Rosenberg P.C.
Ortho -McNeil Pharmaceutical, Inc.
LandOfFree
Imidazolidinedione derivatives for the treatment of diabetes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolidinedione derivatives for the treatment of diabetes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidinedione derivatives for the treatment of diabetes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3510375